{"transactions":[{"id":691879,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Restricted Stock Unit","published_at":"2026-08-11T01:34:08.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001193125-26-343070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526343070/ownership.xml","form_type":"4"}},{"id":691878,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Restricted Stock Unit","published_at":"2026-08-11T01:34:08.000Z","date":"2026-07-17","kind":"exercise","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001193125-26-343070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526343070/ownership.xml","form_type":"4"}},{"id":691877,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Common Stock","published_at":"2026-08-11T01:34:08.000Z","date":"2026-08-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":406,"price":4.07,"value":1652.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs."}],"balance_after":1261,"source":{"system":"sec-edgar","filing":"0001193125-26-343070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526343070/ownership.xml","form_type":"4"}},{"id":691876,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Common Stock","published_at":"2026-08-11T01:34:08.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":1667,"source":{"system":"sec-edgar","filing":"0001193125-26-343070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526343070/ownership.xml","form_type":"4"}},{"id":691875,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Common Stock","published_at":"2026-08-11T01:34:08.000Z","date":"2026-07-17","kind":"exercise","planned":false,"acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":1,"source":{"system":"sec-edgar","filing":"0001193125-26-343070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526343070/ownership.xml","form_type":"4"}},{"id":793770,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T21:29:14.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":11296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":11296,"derivative":{"exercise_price":7.99,"expiration_date":"2033-04-30","underlying":"Common Stock","underlying_shares":11296},"source":{"system":"sec-edgar","filing":"0001493324-26-000002","document":"wk-form4_1777930151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000149332426000002/wk-form4_1777930151.xml","form_type":"4"}},{"id":793769,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T21:29:14.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":25344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":113839,"source":{"system":"sec-edgar","filing":"0001493324-26-000002","document":"wk-form4_1777930151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000149332426000002/wk-form4_1777930151.xml","form_type":"4"}},{"id":1071379,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-08-08T20:31:44.000Z","date":"2025-08-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in full on the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in full on the first anniversary of the date of grant."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-105922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025105922/ownership.xml","form_type":"4"}},{"id":1084029,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-07-21T20:36:20.000Z","date":"2025-07-17","kind":"exercise","planned":false,"acquired":false,"shares":10,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025."}],"balance_after":20,"derivative":{"underlying":"Common Stock","underlying_shares":30},"source":{"system":"sec-edgar","filing":"0000950170-25-097269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025097269/ownership.xml","form_type":"4"}},{"id":1084028,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-21T20:36:20.000Z","date":"2025-07-17","kind":"exercise","planned":false,"acquired":true,"shares":10,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":12,"source":{"system":"sec-edgar","filing":"0000950170-25-097269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025097269/ownership.xml","form_type":"4"}},{"id":1161134,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-03T00:31:33.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":15824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":41572,"derivative":{"exercise_price":5.45,"expiration_date":"2032-04-29","underlying":"Common Stock","underlying_shares":15824},"source":{"system":"sec-edgar","filing":"0001367644-25-000110","document":"wk-form4_1746232287.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764425000110/wk-form4_1746232287.xml","form_type":"4"}},{"id":1161133,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-03T00:31:33.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":34403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":88495,"source":{"system":"sec-edgar","filing":"0001367644-25-000110","document":"wk-form4_1746232287.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764425000110/wk-form4_1746232287.xml","form_type":"4"}},{"id":1228498,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-03-04T21:33:33.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":6,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6},"source":{"system":"sec-edgar","filing":"0000950170-25-032187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025032187/ownership.xml","form_type":"4"}},{"id":1228497,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-03-04T21:33:33.000Z","date":"2025-03-02","kind":"exercise","planned":false,"acquired":false,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024."}],"balance_after":8,"derivative":{"underlying":"Common Stock","underlying_shares":8},"source":{"system":"sec-edgar","filing":"0000950170-25-032187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025032187/ownership.xml","form_type":"4"}},{"id":1228496,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:33:33.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":55,"source":{"system":"sec-edgar","filing":"0000950170-25-032187","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025032187/ownership.xml","form_type":"4"}},{"id":1228495,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:33:33.000Z","date":"2025-03-02","kind":"exercise","planned":false,"acquired":true,"shares":8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":49,"source":{"system":"sec-edgar","filing":"0000950170-25-032187","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025032187/ownership.xml","form_type":"4"}},{"id":1366511,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:04:50.000Z","date":"2024-11-11","kind":"sale","planned":false,"acquired":false,"shares":14287,"price":11.97,"value":171015.39,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 11, 2024, Mr. White sold an aggregate of 14,287 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $11.84 - $12.11. The Company maintains a record of the transactions and copies will be provided upon request."}],"balance_after":54092,"source":{"system":"sec-edgar","filing":"0001367644-24-000184","document":"wk-form4_1731531882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764424000184/wk-form4_1731531882.xml","form_type":"4"}},{"id":1451200,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-07-19T20:34:26.000Z","date":"2024-07-17","kind":"grant","planned":false,"acquired":true,"shares":22325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in three approximately equal annual installments beginning on June 17, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in three approximately equal annual installments beginning on June 17, 2025."}],"balance_after":22325,"derivative":{"underlying":"Common Stock","underlying_shares":22325},"source":{"system":"sec-edgar","filing":"0000950170-24-084950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024084950/ownership.xml","form_type":"4"}},{"id":1500336,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T01:40:48.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":25748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":25748,"derivative":{"exercise_price":5.02,"expiration_date":"2031-05-22","underlying":"Common Stock","underlying_shares":25748},"source":{"system":"sec-edgar","filing":"0001367644-24-000086","document":"wk-form4_1716946839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764424000086/wk-form4_1716946839.xml","form_type":"4"}},{"id":1500335,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-29T01:40:48.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":17430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":68379,"source":{"system":"sec-edgar","filing":"0001367644-24-000086","document":"wk-form4_1716946839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764424000086/wk-form4_1716946839.xml","form_type":"4"}},{"id":1596311,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-03-05T21:06:13.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":9584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."}],"balance_after":9584,"derivative":{"underlying":"Common Stock","underlying_shares":9584},"source":{"system":"sec-edgar","filing":"0000950170-24-025878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025878/ownership.xml","form_type":"4"}},{"id":1596310,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-03-05T21:06:13.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":false,"shares":12917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2023, the reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2023, the reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024."}],"balance_after":25833,"derivative":{"underlying":"Common Stock","underlying_shares":12917},"source":{"system":"sec-edgar","filing":"0000950170-24-025878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025878/ownership.xml","form_type":"4"}},{"id":1596309,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T21:06:13.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":9584,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":67430,"source":{"system":"sec-edgar","filing":"0000950170-24-025878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025878/ownership.xml","form_type":"4"}},{"id":1596308,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T21:06:13.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":true,"shares":12917,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":57846,"source":{"system":"sec-edgar","filing":"0000950170-24-025878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025878/ownership.xml","form_type":"4"}},{"id":1666503,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-30T23:02:50.000Z","date":"2024-01-28","kind":"exercise","planned":false,"acquired":false,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0000950170-24-009002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024009002/ownership.xml","form_type":"4"}},{"id":1666502,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-30T23:02:50.000Z","date":"2024-01-28","kind":"exercise","planned":false,"acquired":true,"shares":4792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":44929,"source":{"system":"sec-edgar","filing":"0000950170-24-009002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024009002/ownership.xml","form_type":"4"}},{"id":1874814,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T23:09:18.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":33847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement."}],"balance_after":50949,"source":{"system":"sec-edgar","filing":"0001367644-23-000109","document":"wk-form4_1685488148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764423000109/wk-form4_1685488148.xml","form_type":"4"}},{"id":1965875,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-07T21:37:02.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":38750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in three approximately equal annual installments beginning on March 2, 2024."}],"balance_after":38750,"derivative":{"exercise_price":2.15,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":38750},"source":{"system":"sec-edgar","filing":"0001209191-23-016774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123016774/doc4.xml","form_type":"4"}},{"id":1965874,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-03-07T21:37:02.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":38750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in three approximately equal annual installments beginning on March 2, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in three approximately equal annual installments beginning on March 2, 2024."}],"balance_after":38750,"derivative":{"underlying":"Common Stock","underlying_shares":38750},"source":{"system":"sec-edgar","filing":"0001209191-23-016774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123016774/doc4.xml","form_type":"4"}},{"id":1965873,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-03-07T21:37:02.000Z","date":"2023-03-03","kind":"exercise","acquired":false,"shares":9582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023."}],"balance_after":19168,"derivative":{"underlying":"Common Stock","underlying_shares":9582},"source":{"system":"sec-edgar","filing":"0001209191-23-016774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123016774/doc4.xml","form_type":"4"}},{"id":1965872,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-07T21:37:02.000Z","date":"2023-03-03","kind":"exercise","acquired":true,"shares":9582,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":40137,"source":{"system":"sec-edgar","filing":"0001209191-23-016774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123016774/doc4.xml","form_type":"4"}},{"id":2042183,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-01-30T18:07:53.000Z","date":"2023-01-29","kind":"exercise","acquired":false,"shares":4791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022."}],"balance_after":4792,"derivative":{"underlying":"Common Stock","underlying_shares":4791},"source":{"system":"sec-edgar","filing":"0001209191-23-005423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123005423/doc4.xml","form_type":"4"}},{"id":2042182,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-30T18:07:53.000Z","date":"2023-01-29","kind":"exercise","acquired":true,"shares":4791,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":30555,"source":{"system":"sec-edgar","filing":"0001209191-23-005423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919123005423/doc4.xml","form_type":"4"}},{"id":2240178,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-06-07T21:23:02.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":28750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As previously disclosed in a Form 4 filed on March 4, 2022, the reporting person was granted 28,750 options on such date.  At the time of the grant, there were insufficient shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan to make the full grant of equity award to the reporting person that was approved for issuance by Aptevo Therapeutics Inc.'s Compensation Committee.  As such, the equity award was split into two separate grants with the first portion of 28,750 options granted on March 4, 2022 and the second portion of 28,750 restricted stock units granted on June 7, 2022, following stockholder approval of an increase in shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU vests in three approximately equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU vests in three approximately equal annual installments beginning on March 3, 2023."}],"balance_after":28750,"derivative":{"underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-22-034873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919122034873/doc4.xml","form_type":"4"}},{"id":2251346,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T20:18:57.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":8446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company."}],"balance_after":17102,"source":{"system":"sec-edgar","filing":"0001367644-22-000091","document":"wf-form4_165402831199670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764422000091/wf-form4_165402831199670.xml","form_type":"4"}},{"id":2350366,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T23:13:08.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":28750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on March 3, 2023."}],"balance_after":28750,"derivative":{"exercise_price":5.3,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-22-016457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000120919122016457/doc4.xml","form_type":"4"}},{"id":2419286,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-02-01T23:01:53.000Z","date":"2022-01-29","kind":"exercise","acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022."}],"balance_after":9583,"derivative":{"underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0001019056-22-000114","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905622000114/white.xml","form_type":"4"}},{"id":2419285,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-01T23:01:53.000Z","date":"2022-01-29","kind":"exercise","acquired":true,"shares":4792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis."}],"balance_after":25764,"source":{"system":"sec-edgar","filing":"0001019056-22-000114","document":"white.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905622000114/white.xml","form_type":"4"}},{"id":2698885,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T21:01:13.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":5027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company."}],"balance_after":8656,"source":{"system":"sec-edgar","filing":"0001367644-21-000087","document":"wf-form4_162189005445348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764421000087/wf-form4_162189005445348.xml","form_type":"4"}},{"id":2854817,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2021-02-18T02:03:29.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":14375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units (the \"RSUs\") convert into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU vests in three approximately equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU vests in three approximately equal annual installments beginning on January 29, 2022."}],"balance_after":14375,"derivative":{"underlying":"Common Stock","underlying_shares":14375},"source":{"system":"sec-edgar","filing":"0001019056-21-000147","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000147/white.xml","form_type":"4"}},{"id":2854816,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-18T02:03:29.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":43125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on January 29, 2022."}],"balance_after":43125,"derivative":{"exercise_price":33.5,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":43125},"source":{"system":"sec-edgar","filing":"0001019056-21-000147","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000147/white.xml","form_type":"4"}},{"id":3013214,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T21:28:28.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":3629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant,  assuming continued service on the Board of Directors."}],"balance_after":3629,"source":{"system":"sec-edgar","filing":"0001367644-20-000151","document":"wf-form4_160193327342258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000136764420000151/wf-form4_160193327342258.xml","form_type":"4"}},{"id":3074064,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"grant","acquired":true,"shares":4813,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant."}],"balance_after":4813,"derivative":{"exercise_price":8.56,"expiration_date":"2030-07-26","underlying":"Common Stock","underlying_shares":4813},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074063,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"grant","acquired":true,"shares":16625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These options vest in full on the one year anniversary of the date of grant."}],"balance_after":16625,"derivative":{"exercise_price":8.56,"expiration_date":"2030-07-26","underlying":"Common Stock","underlying_shares":16625},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074062,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":10828,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 7,219 shares of the issuer's common stock underlying this stock option had vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":21.28,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":10828},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074061,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":10828,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 3,609 shares of the issuer's common stock underlying this stock option had vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":43.82,"expiration_date":"2028-03-09","underlying":"Common Stock","underlying_shares":10828},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074060,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":5414,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award vested over three years, and the final one-third vested on June 1, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":30.1,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":5414},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074059,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":5414,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award vested over three years, and the final one-third vested on February 24, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":27.44,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":5414},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074058,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":14319,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award vested over three years, and the final one-third vested on August 3, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":41.16,"expiration_date":"2026-08-03","underlying":"Common Stock","underlying_shares":14319},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3074057,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:40:57.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":2545,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vested on May 22, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. (\"Emergent\") dated May 22, 2014 of which two-thirds were vested at the time of conversion to issuer's equity pool."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2021-05-22","underlying":"Common Stock","underlying_shares":2545},"source":{"system":"sec-edgar","filing":"0001019056-20-000441","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000441/white.xml","form_type":"4"}},{"id":3200776,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-19T22:35:07.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":303200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on February 17, 2021."}],"balance_after":303200,"derivative":{"exercise_price":0.498,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":303200},"source":{"system":"sec-edgar","filing":"0001019056-20-000244","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000244/white.xml","form_type":"4"}},{"id":3380332,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-06T01:56:36.000Z","date":"2019-11-01","kind":"grant","acquired":true,"shares":189894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on November 1, 2020, the one-year anniversary of the grant date."}],"balance_after":189894,"derivative":{"exercise_price":0.576,"expiration_date":"2029-10-31","underlying":"Common Stock","underlying_shares":189894},"source":{"system":"sec-edgar","filing":"0001019056-19-000620","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000620/white.xml","form_type":"4"}},{"id":3489658,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-14T17:58:00.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":50000,"price":0.88,"value":44000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.88 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.85 to $0.88. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":293603,"source":{"system":"sec-edgar","filing":"0001593968-19-001428","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001428/primary_01.xml","form_type":"4"}},{"id":3518661,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-20T23:22:12.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":30000,"price":0.81,"value":24300.0,"ownership":{"direct":true},"balance_after":243603,"source":{"system":"sec-edgar","filing":"0001593968-19-001149","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001149/primary_01.xml","form_type":"4"}},{"id":3527705,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-15T01:27:33.000Z","date":"2019-05-14","kind":"purchase","acquired":true,"shares":10000,"price":0.78,"value":7800.0,"ownership":{"direct":true},"balance_after":213603,"source":{"system":"sec-edgar","filing":"0001019056-19-000291","document":"white.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000291/white.xml","form_type":"4"}},{"id":3619223,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-05T02:10:25.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":151600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in three approximately equal annual installments beginning on February 28, 2020."}],"balance_after":151600,"derivative":{"exercise_price":1.52,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":151600},"source":{"system":"sec-edgar","filing":"0001019056-19-000186","document":"white.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000186/white.xml","form_type":"4"}},{"id":3741519,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-12-06T15:23:52.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":10000,"price":2.38,"value":23800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $2.38 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $2.38 to $2.39. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":203603,"source":{"system":"sec-edgar","filing":"0001019056-18-001110","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618001110/white_4.xml","form_type":"4"}},{"id":3920678,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Unit Stock","published_at":"2018-05-23T20:08:30.000Z","date":"2018-05-21","kind":"exercise","acquired":false,"shares":35644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were originally issued by Emergent BioSolutions, Inc. (\"Emergent\") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the \"Spin-off\"), each RSU was adjusted and assumed by the Issuer. The RSUs fully vested on May 21, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were originally issued by Emergent BioSolutions, Inc. (\"Emergent\") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the \"Spin-off\"), each RSU was adjusted and assumed by the Issuer. The RSUs fully vested on May 21, 2018."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":35644},"source":{"system":"sec-edgar","filing":"0001019056-18-000739","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000739/white_4.xml","form_type":"4"}},{"id":3920677,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-23T20:08:30.000Z","date":"2018-05-21","kind":"tax_withholding","acquired":false,"shares":8373,"price":5.61,"value":46972.53,"ownership":{"direct":true},"balance_after":193603,"source":{"system":"sec-edgar","filing":"0001019056-18-000739","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000739/white_4.xml","form_type":"4"}},{"id":3920676,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-23T20:08:30.000Z","date":"2018-05-21","kind":"exercise","acquired":true,"shares":35644,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."}],"balance_after":201976,"source":{"system":"sec-edgar","filing":"0001019056-18-000739","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000739/white_4.xml","form_type":"4"}},{"id":3986439,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-21T19:15:05.000Z","date":"2018-03-19","kind":"purchase","acquired":true,"shares":100000,"price":2.93,"value":293000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $2.93 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $2.865 to $3.020, inclusive. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment is being filed to reflect the fact that the reported transaction was a purchase and not a sale of shares of the Issuer by Mr. White. Column 3 of Table I and footnote (1) of this Form 4 as originally filed incorrectly indicated that this transaction was a sale. Those references have been corrected on this amendment to the original Form 4 to reflect that the reported transaction was a purchase."}],"balance_after":166332,"source":{"system":"sec-edgar","filing":"0001019056-18-000465","document":"white_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000465/white_4a.xml","form_type":"4/A","original_submission_date":"2018-03-21"}},{"id":3986437,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-21T15:57:14.000Z","date":"2018-03-19","kind":"sale","acquired":true,"shares":100000,"price":2.93,"value":293000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The selling price of $2.93 is reflective of the weighted average sale price. The prices for the transactions reported on this line range from $2.865 to $3.020, inclusive. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":166332,"source":{"system":"sec-edgar","filing":"0001019056-18-000463","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000463/white_4.xml","form_type":"4"}},{"id":3998475,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2018-03-14T01:41:08.000Z","date":"2018-03-09","kind":"grant","acquired":true,"shares":151600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 9, 2018, the reporting person was granted 151,600 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":151600,"derivative":{"exercise_price":3.13,"expiration_date":"2028-03-09","underlying":"Common Stock","underlying_shares":151600},"source":{"system":"sec-edgar","filing":"0001019056-18-000441","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905618000441/white_4.xml","form_type":"4"}},{"id":4298218,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-06-02T01:42:22.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":75800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the \"Plan\") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three equal annual installments beginning on June 1, 2018."}],"balance_after":75800,"derivative":{"exercise_price":2.15,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":75800},"source":{"system":"sec-edgar","filing":"0001019056-17-000551","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000551/white_4.xml","form_type":"4"}},{"id":4308334,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2017-05-23T21:36:42.000Z","date":"2017-05-22","kind":"exercise","acquired":false,"shares":17828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were originally issued by Emergent on May 22, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on May 22, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were originally issued by Emergent on May 22, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on May 22, 2017."}],"balance_after":35644,"derivative":{"underlying":"Common Stock","underlying_shares":17828},"source":{"system":"sec-edgar","filing":"0001019056-17-000493","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000493/white_4.xml","form_type":"4"}},{"id":4308333,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2017-05-23T21:36:42.000Z","date":"2017-05-22","kind":"exercise","acquired":false,"shares":35643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were originally issued by Emergent BioSolutions, Inc. (\"Emergent\") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the \"Spin-off\"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were originally issued by Emergent BioSolutions, Inc. (\"Emergent\") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the \"Spin-off\"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":53472,"derivative":{"underlying":"Common Stock","underlying_shares":35643},"source":{"system":"sec-edgar","filing":"0001019056-17-000493","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000493/white_4.xml","form_type":"4"}},{"id":4308332,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-05-23T21:36:42.000Z","date":"2017-05-22","kind":"exercise","acquired":true,"shares":17828,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."}],"balance_after":66332,"source":{"system":"sec-edgar","filing":"0001019056-17-000493","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000493/white_4.xml","form_type":"4"}},{"id":4308331,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-05-23T21:36:42.000Z","date":"2017-05-22","kind":"exercise","acquired":true,"shares":35643,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU converts into the Issuer's common stock on a one-for-one basis."}],"balance_after":48504,"source":{"system":"sec-edgar","filing":"0001019056-17-000493","document":"white_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000493/white_4.xml","form_type":"4"}},{"id":4414198,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T17:30:44.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":453,"price":10.3,"value":4665.9,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":36.2,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":453},"source":{"system":"sec-edgar","filing":"0000911916-17-000083","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000083/edgar.xml","form_type":"4"}},{"id":4414197,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T17:30:44.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":1630,"price":36.88,"value":60114.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":9.62,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":1630},"source":{"system":"sec-edgar","filing":"0000911916-17-000083","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000083/edgar.xml","form_type":"4"}},{"id":4414196,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T17:30:44.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":8897,"price":40.26,"value":358193.22,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2026-05-10","underlying":"Common Stock","underlying_shares":8897},"source":{"system":"sec-edgar","filing":"0000911916-17-000083","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000083/edgar.xml","form_type":"4"}},{"id":4414195,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T17:30:44.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":997,"price":38,"value":37886.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":8.5,"expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":997},"source":{"system":"sec-edgar","filing":"0000911916-17-000083","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000083/edgar.xml","form_type":"4"}},{"id":4414194,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T17:30:44.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":6577,"price":37.9,"value":249268.3,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":8.6,"expiration_date":"2025-07-09","underlying":"Common Stock","underlying_shares":6577},"source":{"system":"sec-edgar","filing":"0000911916-17-000083","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000083/edgar.xml","form_type":"4"}},{"id":4421753,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-27T21:06:08.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":75800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in three equal annual installments beginning on February 24, 2018."}],"balance_after":311918,"derivative":{"exercise_price":1.96,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":75800},"source":{"system":"sec-edgar","filing":"0001019056-17-000240","document":"white_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905617000240/white_4.xml","form_type":"4"}},{"id":4502897,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-04T21:22:59.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":453,"price":30.35,"value":13748.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the CoLucid Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash compensation of $13,750."}],"balance_after":453,"derivative":{"exercise_price":36.2,"exercise_date":"2017-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":453},"source":{"system":"sec-edgar","filing":"0000911916-17-000024","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493324/000091191617000024/edgar.xml","form_type":"4"}},{"id":4594169,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":25014,"kind":"person","name":"White Marvin L","position":1,"cik":"0001493324","reported_name":"White Marvin L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-27T19:45:35.000Z","date":"2016-08-03","kind":"grant","acquired":true,"shares":200475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted on August 3, 2016 and vest in three equal installments on August 3, 2017, August 3, 2018 and August 3, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This report has been amended to reflect the 35,643 options that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan."}],"balance_after":236118,"derivative":{"exercise_price":2.94,"expiration_date":"2026-08-03","underlying":"Common Stock","underlying_shares":200475},"source":{"system":"sec-edgar","filing":"0001019056-16-001561","document":"white_4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905616001561/white_4a.xml","form_type":"4/A","original_submission_date":"2016-08-05"}}]}